Pravastatin--ocular side effects after a two year follow-up?
Pravastatin, a new HMG-CoA-reductase inhibitor, was administered to hypercholesterolemic 14 patients with coronary heart disease for a period of two years. This drug reduces the plasma LDL-cholesterol concentrations approximately 30-40%. No development of cataracts or other ocular side effects could be observed during this two year follow-up.